Elsevier

Fertility and Sterility

Volume 94, Issue 3, August 2010, Pages 888-899
Fertility and Sterility

Infertility
A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trial

Presented at the annual meeting of the American Society of Reproductive Medicine, Washington, D.C., October 14–17, 2007.
https://doi.org/10.1016/j.fertnstert.2009.04.022Get rights and content

Objective

To determine the value of gonadotropin/intrauterine insemination (FSH/IUI) therapy for infertile women aged 21–39 years.

Setting

Academic medical center associated with a private infertility center.

Patient(s)

Couples with unexplained infertility.

Intervention(s)

Couples were randomized to receive either conventional treatment (n = 247) with three cycles of clomiphene citrate (CC)/IUI, three cycles of FSH/IUI, and up to six cycles of IVF or an accelerated treatment (n = 256) that omitted the three cycles of FSH/IUI.

Main Outcome Measure(s)

The time it took to establish a pregnancy that led to a live birth and cost-effectiveness, defined as the ratio of the sum of all health insurance charges between randomization and delivery divided by the number of couples delivering at least one live-born baby.

Result(s)

An increased rate of pregnancy was observed in the accelerated arm (hazard ratio [HR], 1.25; 95% confidence interval [CI], 1.00–1.56) compared with the conventional arm. Median time to pregnancy was 8 and 11 months in the accelerated and conventional arms, respectively. Per cycle pregnancy rates for CC/IUI, FSH/IUI, and IVF were 7.6%, 9.8%, and 30.7%, respectively. Average charges per delivery were $9,800 lower (95% CI, $25,100 lower to $3,900 higher) in the accelerated arm compared to conventional treatment. The observed incremental difference was a savings of $2,624 per couple for accelerated treatment and 0.06 more deliveries.

Conclusion(s)

A randomized clinical trial demonstrated that FSH/IUI treatment was of no added value.

Section snippets

Materials and methods

A randomized clinical trial was conducted to evaluate an accelerated treatment strategy for couples with unexplained infertility that consisted of three cycles of clomiphene/IUI and up to six cycles of IVF, compared with a step-wise treatment course of three cycles of clomiphene/IUI, three cycles of gonadotropin/IUI, and up to six cycles of IVF. The study protocol was approved by institutional review boards at the participating institutions. Study participants gave written informed consent. An

Results

Between September 14, 2001 and August 31, 2005, we enrolled 503 couples with unexplained infertility; 247 couples were randomized to a conventional and 256 to an accelerated treatment course (Fig. 1); 493 (98%) couples initiated and 417 (83%) followed the treatment protocol. Nineteen couples were in active treatment as of the closing date of the study. Seventy-nine couples took a break from treatment as follows: 22 couples (11 in each arm) stopped for longer than 6 months but returned to

Discussion

The fast track and standard treatment (FASTT) trial provided the rare opportunity to follow 503 treatment-naïve couples through their entire treatment course, including voluntary hiatuses from care, and to compare two different standardized treatment strategies. In this large randomized controlled trial that compared a conventional treatment paradigm to an accelerated strategy to IVF for infertile couples, it was found that gonadotropin/IUI use was of no added value. Couples in the accelerated

Acknowledgments

We gratefully acknowledge the couples who participated in the trial and the participating insurers Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, and Tufts Health Plan. We thank study research coordinators Allison Diamond, M.P.H., and Rachel Neff, M.P.H., and former REI fellow David Ryley, M.D., for their assistance.

References (27)

  • J.E. Stern et al.

    Assisted reproductive technology practice patterns and the impact of embryo transfer guidelines in the United States

    Fertil Steril

    (2007)
  • C.M. Glazener et al.

    Clomiphene treatment for women with unexplained infertility: placebo-controlled study of hormonal responses and conception rates

    Gynecol Endocrinol

    (1990)
  • Assisted reproductive technology in the United States and Canada: 1993 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry

    Fertil Steril

    (1995)
  • Cited by (183)

    • Economics of Fertility Care

      2023, Obstetrics and Gynecology Clinics of North America
    • Ovarian stimulation and intrauterine insemination

      2023, Handbook of Current and Novel Protocols for the Treatment of Infertility
    View all citing articles on Scopus

    R.H.R. reports receiving fellowship training funds and lecture fees from Ferring, Organon, and Serono before 2005. M.M.R. has nothing to disclose. P.J.N. reports receiving grant support from Elan Pharmaceuticals and Johnson & Johnson, receiving consultant fees from Serono and General Electric, and serving on advisory boards for Merck, Schering Plough, and Abbott; B-S.L. reports receiving an educational grant from Novo Nordisk. K.L.T. reports receiving fellowship training support from Ferring, research grant support from Duramed, Organon, and Serono, consulting fees from Organon, and lecture fees from Organon and Serono. M.M.A. reports receiving unrestricted research grants from Serono and Organon, consulting fees from Serono, and lecture fees from Ferring, Organon, and Serono. M.B.G. has nothing to disclose.

    Supported by a grant from the National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland (R01 HD38561). The National Institute of Child Health and Human Development had no role in the design or conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

    Work was performed at the Department of Obstetrics and Gynecology and Reproductive Biology, Division of Reproductive Endocrinology and Infertility, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Boston IVF, Waltham, Massachusetts; and the Department of Obstetrics and Gynecology, Dartmouth Medical School, Hanover, New Hampshire.

    View full text